Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Introduction Androgen deprivation therapy (ADT) using the luteinizing hormone-releasing hormone (LHRH) agonist or antagonist has been the mainstay treatment of systemic hormone-sensitive prostate cancer. Following an initial decline in PSA levels and a clinically significant response rate of 80–90%, majority…